Diets enriched in monounsaturated fatty acids (MUFA)s have been shown to benefit glycemic control. Furthermore, MUFAs specifically stimulate secretion of the antidiabetic hormone, Glucagon-like peptide-1 (GLP-1) in vitro. To determine whether the MUFA-induced benefit in glycemic tolerance in vivo is due to increased GLP-1 release, lean Zucker rats were pair-fed a synthetic diet containing 5% fat derived from either olive oil (OO; 74% MUFA) or coconut oil (CO; 87% saturated fatty acids; SFA) for 2 weeks. Food intake and body weight gain were similar for both groups over the feeding period. The OO group had improved glycemic tolerance compared with the CO group in both oral and duodenal glucose tolerance tests [area under curve (AUC) 121 Ϯ 61 vs. 290 Ϯ 24 mM⅐120 min, P Ͻ 0.05; and 112 Ϯ 28 vs. 266 Ϯ 65 mM⅐120 min, P Ͻ 0.05, respectively]. This was accompanied by increased secretion of gut glucagon-like immunoreactivity (gGLI; an index of GLP-1 levels) in the OO rats compared with the CO rats (402 Ϯ 96 vs. 229 Ϯ 33 pg/ml at t ϭ 10 min, P Ͻ 0.05). Tissue levels of GLP-1 and plasma insulin and glucagon levels were not different between the two groups. To determine the total contribution of GLP-1 to the enhanced glycemic tolerance in OO rats, the GLP-1 receptor antagonist exendin 9 -39 (Ex 9 -39 ) was infused 3 min before a duodenal glucose tolerance test. Ex 9 -39 abolished the benefit in glycemic tolerance conferred by OO feeding (OOϩEx 9 -39 vs. COϩEx 9 -39 , P ϭ NS), and resulted in a deterioration of glycemic tolerance in the OOϩEx 9 -39 group when compared with the OO controls (AUC 331 Ϯ 21 vs. 112 Ϯ 28 mM⅐120 min, P Ͻ 0.05). To probe the mechanism by which the OO diet enhanced GLP-1 secretion, a GLP-1-secreting L cell line was incubated for 24 h with either 100 M oleic acid (MUFA) or 100 M palmitic acid (SFA) and subsequently challenged with GIP, a known stimulator of the L cell. Preexposure to oleic acid but not to palmitic acid significantly increased GIP-induced GLP-1 secretion when compared with controls (55 Ϯ 12% vs. 34 Ϯ 9%, P Ͻ 0.01). These results demonstrate that the benefit in glycemic tolerance obtained with MUFA diets occurs in association with increased GLP-1 secretion, through a mechanism of enhanced L cell sensitivity. These results suggest that diet therapy with MUFAs may be useful for the treatment of patients with impaired glucose tolerance and/or type 2 diabetes through increased GLP-1 secretion. (Endocrinology 142: 1148 -1155, 2001) T HE INTESTINAL hormone glucagon-like peptide-1 (GLP-1) represents a potential therapeutic agent in the treatment of the insulin resistance and relative insulin deficiency that characterize type 2 diabetes. GLP-1 is one of two major incretin hormones that are secreted from the intestinal tract upon nutrient ingestion and that act to increase insulin secretion. Produced from the proglucagon molecule by tissue-specific posttranslational processing within the ileal L cell (1, 2), GLP-1 is secreted promptly after ingestion of carbohydrate and fat (3, 4). GLP-1 receptor activation within the pancreatic islets results in an increase in glucose-dependent insulin secretion, as well as inhibition of glucagon release (5-10). This ability to decrease glucagon secretion suggests that GLP-1 therapy may also be applicable to patients with type 1 diabetes (11). GLP-1 action in the stomach also reduces gastric acid secretion and gastric motility (12, 13), thereby decreasing the rate at which ingested nutrients are absorbed, whereas in peripheral tissues, GLP-1 may increase sensitivity to insulin (14 -16). Recent evidence also indicates a role for GLP-1 in the central mechanisms that contribute to satiety (17). Therefore, these actions suggest a potential role for GLP-1 in the treatment of patients with diabetes.
T HE INTESTINAL hormone glucagon-like peptide-1 (GLP-1) represents a potential therapeutic agent in the treatment of the insulin resistance and relative insulin deficiency that characterize type 2 diabetes. GLP-1 is one of two major incretin hormones that are secreted from the intestinal tract upon nutrient ingestion and that act to increase insulin secretion. Produced from the proglucagon molecule by tissue-specific posttranslational processing within the ileal L cell (1, 2) , GLP-1 is secreted promptly after ingestion of carbohydrate and fat (3, 4) . GLP-1 receptor activation within the pancreatic islets results in an increase in glucose-dependent insulin secretion, as well as inhibition of glucagon release (5) (6) (7) (8) (9) (10) . This ability to decrease glucagon secretion suggests that GLP-1 therapy may also be applicable to patients with type 1 diabetes (11) . GLP-1 action in the stomach also reduces gastric acid secretion and gastric motility (12, 13) , thereby decreasing the rate at which ingested nutrients are absorbed, whereas in peripheral tissues, GLP-1 may increase sensitivity to insulin (14 -16) . Recent evidence also indicates a role for GLP-1 in the central mechanisms that contribute to satiety (17) . Therefore, these actions suggest a potential role for GLP-1 in the treatment of patients with diabetes.
One approach to the therapeutic use of GLP-1 is to enhance its endogenous secretion, in an effort to avoid the compliance issues related to the necessary injections of peptide hormones. A number of studies have been performed that have examined the factors that regulate the secretion of GLP-1. These have indicated that GLP-1 secretion from the ileal L cell is governed by humoral, neural, and nutrient factors. Glucose-dependent insulinotropic peptide (GIP), a hormone released from the K cells of the duodenum, has been demonstrated to increase the secretion of GLP-1 in several experimental models (18 -20) , although not in humans (10) , whereas somatostatin (18) and insulin (21) are inhibitory to the L cell. Agents of the nervous system such as adrenergic (22) and cholinergic (18, 23, 24) agonists, and the neuropeptide, gastrin-releasing peptide (GRP) (18, 22, 25) , also stimulate GLP-1 secretion. However, as the L cells of the ileum are also exposed to luminal contents, perhaps the most im-portant regulation of GLP-1 secretion is derived from digested nutrients, particularly carbohydrate and fat. Both carbohydrates and fat potently stimulate the secretion of GLP-1 (3, 4) and appear to act in an indirect manner because peak GLP-1 levels occur within 30 min of nutrient ingestion, a time frame that is not consistent with the delivery of these nutrients to the ileal L cell (26) . However, certain fatty acids have also been shown to directly stimulate the L cell. Specifically, it has been determined that monounsaturated fatty acids (MUFA) are stimulatory to GLP-1 secretion, whereas saturated fatty acids (SFA) are not (27) . Furthermore, the chain length of the fatty acid is an important factor in determining GLP-1 secretion, as only long chain MUFA (ՆC16) were found to stimulate the L cell in vitro.
MUFA diets are being increasingly advocated for use in the treatment of patients with type 2 diabetes. Previously, diets high in carbohydrate content were recommended to patients with diabetes, primarily to decrease the cardiovascular risks associated with high levels of saturated fat (28) . However, diets high in carbohydrate may be detrimental to glycemic control (29) . In contrast, several studies have demonstrated that diets with increased proportions of MUFAs, compared with high carbohydrate diets, produce improvements in glycemic control and also provide benefit to lipid profiles [e.g. decreased triglycerides and very low-density lipoprotein (29 -35) ]. Glucagon levels are also elevated in patients who are fed diets high in carbohydrates compared with high MUFA diets (29) . Given the benefits to glucose homeostasis produced by the many actions of GLP-1, and the finding that MUFAs potently stimulate the secretion of GLP-1 in vitro, the present study was undertaken to explore the potential link between increased GLP-1 secretion and the benefits in glycemia induced by diets containing MUFAs compared with SFAs.
Materials and Methods

Diets and feeding
Lean Zucker male rats (Fa/?; Charles River Laboratories, Inc. Canada Inc., St. Constant, Canada) were used at 7-8 weeks of age in all experiments. All animal procedures were approved by the Animal Care Committee of the University of Toronto. The animals were acclimatized in individual cages with free access to food and water for 1 week. Chow was provided in separate canisters, which were used to determine daily food intake. Subsequent to the acclimatization period, groups of animals were pair-fed on synthetic diets enriched with either MUFAs or SFAs. The dietary composition and energy content of each diet are listed in Table 1 . In brief, each diet was composed of 75% carbohydrates, 20% protein, and 5% fat (Harlan Teklad, Madison, WI). The fat component of the MUFA diet was derived entirely from olive oil (74% MUFA), whereas the fat component of the SFA diet was derived entirely from coconut oil (87% SFA). All other constituents of the synthetic diets were identical between the two groups. Rats were maintained on the synthetic diets for a period of 2 weeks during which food intake and body weight were monitored daily. Following the 2-week feeding period, rats were fasted overnight (commencing at 1700) and underwent experiments the following day (commencing at 0900). Fasting glycemia was 4.5 Ϯ 0.3 mm across all experiments.
Glucose tolerance tests
Oral glucose tolerance tests (OGTT) were performed on conscious animals. In brief, a bolus of 10% glucose was administered by gastric gavage at a dose of 1 g/kg body weight. Tails were anesthetized with Xylocaine (Astra Pharma, Mississauga, Ontario, Canada) and blood samples were obtained at t ϭ 0, 10, 20, 30, 60, 90, and 120 min for determination of blood glucose using a One Touch Basic blood glucose monitoring system (Lifescan Canada Ltd., Burnaby, British Columbia, Canada).
Duodenal glucose tolerance tests (DGGT) were also performed to avoid any potential effects of GLP-1 on gastric emptying (13) . Rats were anesthetized with 60 mg/kg pentobarbital, and the portal vein was cannulated for blood sampling. A bolus of 10% glucose (1 g/kg body weight) was injected into the duodenum, and blood samples were obtained from the tail vein as for the OGTT. In addition, blood was also collected from the portal vein into 10% (vol/vol) Trasylol (5000 Kalikrein Inactivating Units/ml; Bayer Corp., Inc., Etobicoke, Ontario, Canada)-EDTA (12 mg/ml)-diprotin A (34 g/ml; Calbiochem, La Jolla, CA), and plasma was stored at Ϫ20 C until time of RIA. In some experiments, Ex (9 -39) (Bachem California, Inc., Torrance, CA), a GLP-1 receptor antagonist (36), or vehicle control was administered as a bolus dose through a jugular cannula at a dose of 18.3 nmol/kg (61.7 g/kg), 3 min before the administration of duodenal glucose. This protocol was derived from a similar study in which Ex (9 -39) infusion antagonized the effect of GLP-1 on glycemic profiles in rats (37) .
GLUTag cell cultures
The GLUTag cell line is an L cell model derived from intestinal tumors induced in transgenic mice by expression of the SV40 large T antigen under the control of the proglucagon promoter (38) . GLUTag cultures were maintained in DMEM with 10% FBS. At the time of experiment, GLUTag cells were trypsinized and plated into 24-well culture plates and allowed to grow to 60 -80% confluence. The cells were then rinsed with HBSS and exposed to either normal experimental media (DMEM with 1% FBS; control), or experimental media containing either 100 m oleic or palmitic acid (Sigma, St. Louis, MO) for 24 h. Media was then removed and replaced with either normal experimental media or media containing 100 nm human GIP (Bachem California, Inc. Torrance, CA) for 2 h. Following the incubation period, media were collected in trifluoroacetic acid (TFA) to a final concentration of 0.1% and small peptides and proteins were extracted by reversed-phase adsorption on a C 18 silica cartridge (C 18 Sep-Pak, Waters Associates, Milford, MA). The recovery of intact proglucagon-derived peptides with this protocol is greater than 88% (39).
Assays
Plasma samples were analyzed by RIA for gGLI, which correlates directly with GLP-1 levels in the rat in vivo (23) . Briefly, gGLI is derived by subtracting immunoreactive glucagon (IRG), determined in 0.2 ml plasma using antiserum 04A (Dr. R. H. Unger, Dallas, TX), from total glucagon-like immunoreactivity (GLI), determined using 0.1 ml plasma with antiserum K4023 (Biospacific, Emeryville, CA). Plasma insulin levels were determined using an immunoreactive insulin kit (Linco Research, Inc., St. Charles, MO).
Five-centimeter segments of ileum were homogenized in 1 n HCl containing 5% (vol/vol) HCOOH, 1% (vol/vol) TFA, and 1% (vol/vol) NaCl. Extraction of small peptides and proteins was carried out by reversed-phase adsorption, as above. Ileal and cell culture media extracts were analyzed by RIA for GLP-1 using a GLP-1 antiserum (Affiniti a The two diets differed only in the use of OO or CO to provide the fat component.
Research Products, Mammead, UK) directed against the carboxyterminus of the peptide. This antiserum has been shown to recognize predominantly GLP-1 (7-36NH2) in extracts of ileum and GLUTag cells (38, 40) . Protein levels in ileal extracts were assayed by the Lowry Protein method (41) .
Fatty acid composition of the plasma was determined by gas chromatography in the laboratory of Dr. S. Cunnane (University of Toronto, Toronto, Ontario, Canada), as previously described (42) .
Data analysis
Area-under-the-curve (AUC) of glycemic profiles was determined according to the trapezoidal rule. All data are expressed as mean Ϯ sem. Statistical analysis was assessed by Student's t test or ANOVA followed by n-1 posthoc custom hypothesis tests, as appropriate, on Statistical Analysis System Software (SAS Institute, Inc., Cary, NC). Significance was established to be at the P Ͻ 0.05 level.
Results
Food intake and body weight
Food intake during the paired feeding protocol was monitored daily and did not differ significantly between the OO group and the CO group for the duration of the feeding period (Fig. 1A) . As a result, the two groups of rats gained weight at similar rates over the 2-week course of feeding (Fig.  1B) . As deficiencies in the levels of essential fatty acids can cause impaired glucose tolerance (43) , circulating essential fatty acids were determined in rats from each group. Levels of essential fatty acids were not significantly different between the two groups of animals (Fig. 1C) , consistent with previous studies demonstrating that a two week feeding protocol preserves the levels of essential fatty acids (44, 45) .
Oral glucose tolerance tests
Following the 2-week feeding period, rats in both the OO and CO groups were challenged with an oral load of glucose and blood glucose was monitored over the following 2-h period. Overall, glycemic responses were reduced in rats that received the OO diet compared with those rats fed the CO diet ( Fig. 2A) . OO-fed rats displayed a lower peak in glycemia when compared with the CO group (P Ͻ 0.05). Furthermore, the OO group demonstrated better glycemic tolerance as evidenced by the return to baseline in blood glucose at t ϭ 120 min in the OO but not the CO group (P Ͻ 0.05). When the glycemic response was quantified over the entire 120-min period, OO-fed rats were found to have a significantly reduced glycemic AUC compared with CO-fed rats (121 Ϯ 61 vs. 290 Ϯ 24 mm⅐120 min, respectively P Ͻ 0.05) (Fig. 2B) .
Duodenal glucose tolerance tests
In a separate group of animals, DGTTs were performed to avoid the inhibitory effects of GLP-1 on gastric emptying (13) . Similar results to those achieved with the OGTTs were obtained in this set of experiments (Fig. 3A) , such that peak glycemia was again lower and blood glucose returned to baseline in OO-fed rats in contrast to the rats fed the CO diet (Fig. 3A) . The glycemic AUC was also significantly reduced in the OO compared with the CO group (112 Ϯ 28 vs. 266 Ϯ 65 mm⅐120 min, respectively. P Ͻ 0.05) (Fig. 3B) . During the DGTTs, blood was also sampled from the portal vein for the determination of hormone levels. Although insulin and glucagon levels were not different between the two groups of animals (Fig. 4) , plasma gGLI levels were significantly elevated at the 10 min time-point in the OO-fed rats as compared with the CO group (402 Ϯ 96 pg/ml vs. 229 Ϯ 33 pg/ml respectively, P Ͻ 0.05) (Fig. 5A) . In contrast, the ileal content of GLP-1 was not significantly different between the OO-and CO-fed rats (Fig. 5B) .
Duodenal glucose tolerance tests ϩ Ex (9 -39) infusions
To establish whether different GLP-1 levels between the OO-and CO-fed groups were responsible for the observed differences in glucose tolerance, DGTTs were carried out with concomitant administration of the GLP-1 receptor antagonist, Ex (9 -39). Preinfusion of Ex (9 -39) completely abolished the observed benefit in glucose tolerance produced by the OO diet (Fig. 6) . Peak glucose levels were higher, glycemia remained elevated above baseline for the entire experimental period, and the glycemic AUC was elevated in OO-fed rats that received Ex (9 -39) compared with OO rats receiving a saline (control) infusion (331 Ϯ 21 vs. 112 Ϯ 28 mm⅐120 min, P Ͻ 0.05; Fig. 6C ). In contrast, Ex (9 -39) treatment did not alter the glycemic response to an oral glucose challenge in CO-fed rats (272 Ϯ 120 vs. 266 Ϯ 65 mm⅐120 min [COϩEx 9 vs. COϩsaline]). Plasma insulin levels were not significantly different between the OO-and the CO-fed rats throughout the experimental period (data not shown), however, after infusion with Ex (9 -39), glucagon levels rose dramatically and to a similar extent in both the OO-and CO-fed animals (Fig. 7) .
Effects of MUFA and SFA on GIP-induced GLP-1 secretion in vitro
To determine the effects of chronic exposure to MUFA and SFA on the L cell response to secretagogues, GLUTag cells were preincubated for 24 h in media alone or media containing either oleic acid (MUFA) or palmitic acid (SFA). The 24-h pretreatment was then followed by a 2-h challenge with GIP, a known stimulator of GLP-1 secretion from the L cell (18 -20) . Pretreatment with either oleic acid or palmitic acid did not change basal secretion of GLP-1 from that observed in cells treated with media alone (Fig. 8) . In cells preincubated with media alone, treatment with GIP resulted in a 34 Ϯ 9% (P Ͻ 0.05) increase in GLP-1 secretion. In contrast, in cells preincubated with oleic acid, GIP not only induced a significant increase in GLP-1 secretion (by 55 Ϯ 12%; P Ͻ 0.01), but this increase was significantly greater than that observed in cells that were preincubated with media alone (P Ͻ 0.01). Preincubation of GLUTag cells with media containing 100 m palmitic acid diminished the subsequent GLP-1 response to the same challenge with GIP (P ϭ NS).
Discussion
The benefits of diets rich in MUFAs have been reported to include improvements in both lipid status and glycemic control (28 -35, 46) . However, few studies have attempted to investigate the mechanisms by which dietary MUFAs mediate these benefits. The demonstration of increased secretion of the antidiabetic hormone GLP-1 in rats following 2 weeks of feeding with an OO diet provides one mechanism for the observed benefit of MUFA to glycemic tolerance. OO feeding, in contrast to feeding with CO, was associated with improvements in glycemic tolerance in rats, as evidenced by lower glycemic AUCs in response to both oral and duodenal glucose tolerance tests. In association with the observed benefit in glycemic tolerance achieved in this study was the concomitant increase in the secretion of gGLI, a molecule released in parallel with the antidiabetic hormone GLP-1 (23) . An alternative perspective on this finding is that chronic CO feeding acted to depress GLP-1 secretion in this setting. However, this seems unlikely because oleic acid, the main fatty acid constituent of OO, has been demonstrated to significantly increase GLP-1 secretion in intestinal cultures in vitro (27) . Consistent with this finding, OO, but not butter, also stimulates GLP-1 secretion acutely in humans (47) .
Curiously, the benefit in glycemic tolerance observed in the MUFA-fed rats persisted for the entire experimental time period (120 min), even though GLP-1 secretion was elevated only at the early time point of the experiment (10 min). This pattern of GLP-1 secretion is consistent with stimulation of the L cell through indirect mechanisms (36, 37) because glucose is rapidly absorbed in the proximal regions of the gastrointestinal tract (36, 37) . Thus, glucose does not progress to the distal location of the majority of the L cells under phys- Immunoreactive glucagon levels in rats receiving Exendin (9 -39) infusions prior to A duodenal glucose tolerance test. Immunoreactive glucagon (IRG) levels during a duodenal glucose tolerance test. Both olive oil-(solid line) and coconut oil-fed rats (dashed line) received a bolus injection of exendin(9 -39) 3 min before the duodenal glucose tolerance test. iological conditions and is therefore incapable of eliciting later peaks in GLP-1 secretion. Therefore, to clearly define the contribution of increased GLP-1 secretion to the benefit in glycemic tolerance induced by MUFA feeding, experiments using a specific inhibitor of the GLP-1 receptor were undertaken. Ex (9 -39) is a peptide homologue of GLP-1 isolated from the venom of the Gila monster and has been demonstrated to be a potent antagonist at the GLP-1 receptor (36, 37) . Although Ex (9 -39) may also interact with the GIP receptor in vitro, this only occurs at extremely high concentrations [1-10 m (48)], and it is therefore believed that the actions of Ex (9 -39) in vivo are largely mediated through the GLP-1 receptor. Ex (9 -39) administration before a duodenal glucose challenge in rats fed OO completely abolished the benefit in glycemic tolerance obtained with this diet, therefore demonstrating that the beneficial effects of MUFA feeding on glucose tolerance are specific to activation of the GLP-1 receptor. A similar experiment conducted in the CO group did not significantly alter the glycemic response to the duodenally administered glucose challenge, consistent with the observation that GLP-1 secretion was not elevated in this group. It may also be postulated that the CO diet partly decreased glucose tolerance in the present study, as SFA have been associated with decreases in insulin sensitivity (49, 50) . However, the results of the Ex (9 -39) study clearly implicate GLP-1 as a causative factor in the enhanced glycemic tolerance conferred by MUFA feeding in the present study.
The fact that the benefit in glycemic tolerance induced by OO feeding in OGTTs was maintained in DGTTs indicates that differences in the rates of gastric emptying were not responsible for the MUFA-induced improvement in glycemic tolerance. This is an important finding, as GLP-1 is known to inhibit gastric emptying as part of its ability to improve glycemic handling (12, 13) . Also, as tissue levels of GLP-1 were not significantly different between the two groups of rats, altered synthesis of GLP-1 cannot account for the increased secretion of GLP-1 observed in the OO-fed group. This is also consistent with the fact that fatty acids do not affect total cell content of GLP-1 in vitro (27) . Furthermore, the increase in GLP-1 secretion in rats fed OO was not associated with alterations in the plasma levels of either insulin or glucagon. In support of this finding is a recent report that demonstrated that elevated secretion of GLP-1 did not alter insulin levels in normal humans fed a meal supplemented with OO (47) . Similarly, GLP-1 administration during an OGTT in rats improves glycemic tolerance in the absence of any effect on insulin secretion (51) . Given that the primary stimulator of insulin secretion is the level of glycemia, the fact that glucose levels were diminished in the OO rats despite unaltered plasma levels of insulin demonstrates that the amount of insulin secreted per unit of glycemia must have increased as a result. Therefore, the enhanced secretion of GLP-1 observed in the present study may have benefited glycemic tolerance through its stimulatory effects on the ␤ cell despite the fact that plasma levels of insulin were not different.
However, in this model it is not possible to accurately define the site of the benefit to glycemic tolerance induced by the increased secretion of GLP-1. Thus, the decreased levels of glycemia accompanied by unchanged insulin levels observed in OO-fed rats may also be explained by extrapancreatic-extragastric functions of GLP-1 acting to enhance insulin sensitivity. In support of this concept, GLP-1 has been reported to stimulate glycogen formation in liver cells (52) , and GLP-1 receptors have been identified in both muscle and adipose tissue (16, 53, 54) . GLP-1 also enhances insulindependent and insulin-independent glucose disposal in dogs and humans, respectively (14 -16) , although this remains controversial (55) . In addition, high-MUFA diets can improve glycemic control when compared with diets high in carbohydrate (46, 56) and have been shown to enhance insulin sensitivity (35) . Interestingly, the effects of the qualitative features of dietary fat on insulin sensitivity were examined recently, demonstrating that chronic feeding of diets high in MUFAs improved insulin sensitivity compared with a high SFA diet in healthy human volunteers (33) . It is not known whether the dietary manipulation altered the secretion of GLP-1 in these experiments. Additionally, the experiments using the GLP-1 receptor antagonist, Ex (9 -39), demonstrated that the deterioration of glycemic tolerance in OO rats was partly attributable to the elevated secretion of glucagon, consistent with a role for GLP-1 in the inhibition of secretion from the ␣ cell. However, similar increments in glucagon release were also observed in the CO rats, without a comcomitant rise in glycemia. Therefore, the improvements in glycemic tolerance mediated by enhanced secretion of GLP-1 witnessed in the present study are likely attributable to effects on peripheral insulin-sensitive tissues.
Of some interest was the finding that GLP-1 secretion in the OO-fed rats was elevated above basal levels very early during the glucose challenge. Similar rapid increments in GLP-1 secretion have also been observed in humans (3, 4) . These findings are inconsistent with the fact that nutrients do not reach the ileal L cell within this time frame (26) and have led to the hypothesis that the early phase of nutrient-induced GLP-1 secretion may be mediated indirectly (57, 58) . Indeed, previous studies from our lab have demonstrated that proximal nutrients are incapable of stimulating GLP-1 secretion in the absence of the distal gut (36, 37) . In the rat, this indirect regulation of GLP-1 secretion is mediated through complex interactions between the endocrine and nervous systems and involves the enteric hormone GIP (58) and the vagus nerve (23) . However, GIP can also directly stimulate the L cell (18 -20) , and for this reason, was used to investigate the potential mechanism of action of MUFAs on the L cell. Exposure to oleic acid for 24 h before a 2 h challenge with GIP led to a greater stimulation of GLP-1 secretion compared with the secretion elicited by the same dose of GIP in cells preexposed to media alone. Furthermore, preexposure of the L cells to palmitic acid, a SFA, caused a blunting in the GLP-1 secretion induced by GIP. Therefore, it appears that chronic exposure to MUFAs can enhance the sensitivity of the L cell to subsequent stimulation, resulting in greater levels of GLP-1 secretion, whereas SFAs depress the secretory response to the same stimulus. The cellular mechanism(s) underlying these responses is not known, however, several factors may be speculated to play a role. For example, PKChas been reported to be preferentially activated by unsaturated as opposed to saturated fatty acids (59, 60) and therefore may be implicated in this process. PKC is a known intracel-lular mediator of GLP-1 secretion (39) , and the intestinal L cell expresses the isoform of this enzyme (Rocca, A. S., and P. L. Brubaker, unpublished observations). Alternatively, the increased L cell sensitivity to GIP induced by oleic acid may occur consequent to altered membrane fluidity (61) , possibly through changes in activity of the intestinal fatty acid binding protein (I-FABP). I-FABP is present in the intestinal L cell (Rocca, A. S., and P. L. Brubaker, unpublished observations) and this molecule is known to influence cell membrane structure and function (62, 63) . Further experimentation is clearly required to identify the intracellular mechanism(s) that is responsible for the MUFA-induced increase in L cell sensitivity to GIP stimulation.
In conclusion, the benefits in glycemic control that have been ascribed to diets enriched with MUFAs can be explained, at least in part, by the fact that such diets increase secretion of the antidiabetic hormone GLP-1. Manipulation of dietary fatty acid composition to increase the proportion of MUFAs relative to SFA, may therefore be a useful approach with which to increase the secretion of GLP-1 in patients with impaired glucose tolerance or type 2 diabetes.
